Glenmede Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Glenmede Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$839K	Buy	+4,739	New	+$705K	﹤0.01%	754

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Investment Management's LGND Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2025: 4,739 shares worth $839K. The stake represents ﹤0.01% of the portfolio and ranks #754 among its holdings.

314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

Glenmede Investment Management held 4,739 shares of Ligand Pharmaceuticals worth $839K as of Q3 2025.
Ligand Pharmaceuticals was a new Glenmede Investment Management position in Q3 2025.
Ligand Pharmaceuticals made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #754 holding.
314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.